2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12B.03 Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions

EP.12B.03 Cognitive Impact of Lorlatinib Administration in Advanced Non Small Cell Lung Cancer with ALK and ROS1 Fusions

Back to course

Pdf Summary

The study focuses on the cognitive effects of lorlatinib, an advanced NSCLC (Non-Small Cell Lung Cancer) treatment targeting ALK or ROS1 fusions, noting its ability to penetrate the brain and its unique safety profile that includes potential neurocognitive adverse events. Researchers from the IRCCS Regina Elena National Cancer Institute aimed to assess the neurocognitive impact on pretreated patients with NSCLC who were administered lorlatinib as a second or subsequent line of treatment.<br /><br />Various cognitive functions were evaluated, such as abstract reasoning, long-term memory, verbal learning, executive functions, attention, short-term memory, and visuo-constructional abilities. These assessments were conducted before starting lorlatinib treatment and after a median duration of 12 months of therapy.<br /><br />Findings indicate that a small percentage (6%) of patients experienced neurocognitive deficits during treatment. It was noted that patients who had previously undergone brain radiotherapy (RT) could exhibit affected cognitive functions when treated with lorlatinib. However, long-term use of lorlatinib, extending beyond 6 months, did not further deteriorate neurocognitive functions.<br /><br />The study suggests no unexpected adverse events were recorded, with 26% of the patients experiencing grade 2 adverse effects that necessitated a dose reduction. Researchers propose to increase the patient sample size to further evaluate the cognitive impact of lorlatinib when used as a first-line treatment.<br /><br />In summary, lorlatinib shows promise as a treatment for ALK-positive advanced NSCLC, with a relatively minor impact on neurocognitive functions, and the findings encourage further research to better understand its safety and efficacy profile.

Asset Subtitle

Fabiana Cecere

Meta Tag

Speaker Fabiana Cecere

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

lorlatinib

cognitive effects

NSCLC

ALK fusions

ROS1 fusions

neurocognitive adverse events

brain penetration

Regina Elena National Cancer Institute

neurocognitive impact

dose reduction